Can Scleroderma Go Into Remission?

Scleroderma does not follow a simple on-off switch between active disease and full remission the way some autoimmune conditions do. In localized scleroderma (morphea), genuine remission is common, though relapses happen in a sizeable number of patients. In systemic sclerosis, the more serious form, the word “remission” is used cautiously by specialists: skin thickening can improve dramatically over time, organ involvement can stabilize, and disease activity scores can drop to near zero, but the underlying autoimmune process rarely disappears entirely. Still, some aggressive newer therapies have begun producing outcomes that look closer to remission than anything previously seen.

Why Doctors Hesitate to Say “Remission” in Systemic Sclerosis

Systemic sclerosis (SSc) involves fibrosis and vascular damage that can affect the skin, lungs, heart, kidneys, and digestive tract. Even when disease activity quiets down, the structural damage it leaves behind often persists. Fibrotic tissue in the lungs does not simply dissolve, and blood vessels narrowed by the disease stay narrowed. So a patient might have no measurable disease activity and still live with significant functional consequences from earlier damage. Researchers have developed scoring systems to measure disease activity, drawing on factors like skin thickening, lung function, inflammatory markers, and the presence of digital ulcers or tendon friction rubs. A revised European activity index identifies “active” disease when a patient scores 2.5 or above on a 10-point scale, using items such as worsening skin scores, elevated C-reactive protein, reduced lung diffusion capacity, and the presence of digital ulcers or tendon friction rubs.¹ Falling below that threshold is considered “inactive” disease, and it is the closest thing most systemic sclerosis patients get to remission.

The distinction matters because it shapes expectations. A patient told they are “in remission” might assume the disease is gone. In systemic sclerosis, inactivity is a more honest term: the immune system has stopped actively attacking tissues, but the scars remain, and monitoring stays important because flares can return.

Skin Thickening Often Improves on Its Own

One of the more encouraging aspects of diffuse cutaneous systemic sclerosis (dcSSc) is that skin fibrosis frequently softens over time without any treatment specifically aimed at the skin. Among patients who survive the first few years, up to two-thirds experience striking improvement in skin thickening, and that improvement is associated with better overall survival.² A large European registry analysis found that about a quarter of dcSSc patients showed measurable improvement in skin fibrosis over one year of follow-up, while only about one in ten progressed. Patients who started with more severe skin involvement and did not have tendon friction rubs were actually the most likely to improve.³

This natural softening of the skin is real, but it comes with an important caveat. One trajectory study found that the patients whose skin scores improved the most were actually the group with the highest frequency of serious internal organ complications.⁴ In other words, softer skin does not automatically mean the disease is quieter inside. The relationship between skin involvement and visceral complications is more tangled than you might expect, which is one reason doctors track multiple organ systems rather than relying on skin alone as a barometer.

The Lung Problem

Interstitial lung disease (ILD) is one of the most common and feared complications of systemic sclerosis, and it is the area where “remission” is hardest to achieve. Fibrotic scarring in the lungs tends to be permanent. The realistic goal for most patients is stabilization: keeping lung function from declining further. Two therapies approved in recent years, nintedanib and tocilizumab, were shown in randomized trials to slow the loss of lung function in SSc-ILD.⁵ In a trial of tocilizumab, patients in the treatment arm lost less than 1% of their forced vital capacity over 48 weeks, compared with a 4% decline in the placebo group. The drug also appeared to slow the progression of fibrosis visible on chest imaging.

Stabilization is genuinely meaningful here. Even modest ongoing lung function decline translates to worsening breathlessness and exercise tolerance over time, so holding the line is a significant win. But reversing established lung fibrosis remains beyond what current therapies can do for most patients.

Pulmonary Arterial Hypertension and Kidney Crisis

Two other organ-level complications shape the remission question in different ways. Pulmonary arterial hypertension (PAH), where blood pressure rises in the arteries feeding the lungs, affects roughly 8 to 15% of systemic sclerosis patients depending on how it is diagnosed. It is more common in the limited cutaneous form of the disease. PAH remains one of the leading causes of death in scleroderma, with two-year survival reported around 40% in patients with isolated PAH compared with about 80% in those without it.⁶ PAH can be managed with vasodilator therapies, but it does not go into remission in the way that skin disease can.

Scleroderma renal crisis (SRC) is a different story. It is a sudden, dangerous spike in blood pressure that can shut down kidney function, occurring primarily in patients with diffuse disease. The introduction of ACE inhibitors dramatically improved survival from this complication, but even with early aggressive treatment, about 40% of patients need dialysis, and five-year mortality remains in the range of 30 to 40%.⁷ Some patients recover enough kidney function to come off dialysis over the following months, but SRC leaves lasting damage. The takeaway is that major organ involvement in systemic sclerosis tends to create permanent changes. Treatments buy time, slow progression, and sometimes partially restore function, but the word “remission” remains an overstatement for most organ complications.

Stem Cell Transplantation Gets the Closest to True Remission

If there is a treatment that comes closest to inducing remission in severe systemic sclerosis, it is autologous hematopoietic stem cell transplantation (AHSCT). The idea is to wipe out the dysfunctional immune system with high-dose chemotherapy and then rebuild it from the patient’s own stem cells. Among patients with rapidly progressive diffuse disease and lung involvement, AHSCT has emerged as one of the most effective strategies for conferring a survival benefit in randomized trials.⁸

A landmark trial using a myeloablative transplant protocol found that transplanted patients had better event-free and overall survival compared with those on standard immunosuppression, though the approach came with serious upfront toxicity, including treatment-related deaths.⁹ Long-term follow-up data from earlier transplant cohorts showed that about 81% of patients had a clinically beneficial response after a median follow-up of over five years, with sustained improvement in skin thickening and stabilization of organ function lasting up to seven years.¹⁰ Event-free survival (meaning no death, relapse, or organ failure) was about 64% at five years and 57% at seven years in that cohort.

These numbers are genuinely impressive for a disease as relentless as severe dcSSc, but they also make clear that even after transplantation, a substantial minority relapses or progresses. AHSCT is reserved for patients with aggressive, treatment-resistant disease because the procedure itself carries real risks. It is not a realistic option for most scleroderma patients, but for the right candidates, it offers the most remission-like outcomes currently available.

CAR T-Cell Therapy and the Frontier of Deep Remission

The newest development generating excitement is CAR T-cell therapy, borrowed from cancer treatment. In this approach, a patient’s T cells are engineered to target and destroy B cells expressing a marker called CD19. The first reported case of a patient with severe, treatment-resistant systemic sclerosis receiving CD19-targeted CAR T cells was published in 2023.¹¹ Since then, a small case series with a median follow-up of 15 months reported that all systemic sclerosis patients treated had a decrease in their EUSTAR disease activity index, and every patient in the broader autoimmune series was able to stop immunosuppressive therapy entirely.¹²

These early results are striking, but the evidence base is tiny. We are talking about handfuls of patients followed for roughly a year or two. Whether these responses hold up over five or ten years is unknown. Whether CAR T therapy can reverse established organ damage, or only quiet the immune attack, remains unclear. The treatment is expensive, complex, and carries its own risks, including a period of immune suppression while B cells are wiped out and slowly recover. But the fact that immunosuppressive drugs could be stopped entirely in early cases has generated more optimism about deep remission in systemic sclerosis than specialists have felt in decades.

Localized Scleroderma Has a Much Better Remission Story

Localized scleroderma, also called morphea, is a fundamentally different disease from systemic sclerosis, even though they share a name. Morphea involves patches or bands of skin thickening without the internal organ involvement that defines systemic disease. It genuinely can go into remission, and most patients eventually do achieve inactive disease.

In children, the most commonly used treatment is methotrexate, which achieves a response rate around 77% in patients who receive systemic therapy.¹³ But remission in morphea does not always mean the disease is gone for good. In a cohort of pediatric patients followed for more than two years who had achieved remission, roughly 45% eventually relapsed. Patients who were older at disease onset, had positive antinuclear antibodies (ANA), and lacked extracutaneous involvement were more likely to relapse. The average time from completing treatment to first relapse was about 21 months.¹⁴ Another study found that about 22% of pediatric patients experienced at least one relapse, with the first flare typically occurring around 20 months after stopping treatment, and that delays in starting systemic treatment were associated with higher relapse rates.¹⁵

Adults with morphea tend to have a harder time than children. A study tracking disease activity over time found that adults and patients with the generalized subtype were more likely to experience recurrence. Among patients with the generalized subtype, 43% had recurrence of disease activity, compared with 21% of those with the linear subtype, and the time to first recurrence was shorter in the generalized group.¹⁶ Of patients followed for at least five years, over a third had experienced at least one recurrence.

The practical message for morphea patients: remission is realistic, but monitoring afterward matters, especially in the first two years after stopping treatment.

Autoantibodies Help Predict Who Does Better

One of the more useful tools for forecasting how systemic sclerosis will behave is the specific autoantibody a patient carries. Anti-centromere antibodies (ACA) are linked to limited cutaneous disease and lower risk of lung involvement, while anti-Scl-70 (anti-topoisomerase I) antibodies are associated with diffuse skin disease and a higher chance of lung fibrosis.¹⁷ Other less common antibodies carry their own prognostic patterns: anti-RNA polymerase III antibodies are linked to diffuse disease and a higher risk of renal crisis, while anti-Th/To antibodies, though associated with limited skin disease, may signal a greater chance of developing pulmonary hypertension.

Recent single-cell research has started to reveal why these antibody subgroups behave differently. Early diffuse-cutaneous patients with anti-topoisomerase antibodies showed fibroblast-driven fibrotic responses dominated by one growth factor pathway, while those with anti-RNA polymerase III antibodies showed a pattern dominated by endothelial cell activation instead.¹⁸ These differences at the cellular level help explain why patients with different antibody profiles can follow such different trajectories in skin thickening and organ involvement, and why “remission” might mean different things depending on your antibody subtype.

Children With Systemic Sclerosis Generally Fare Better

When systemic sclerosis appears in childhood, the overall trajectory is typically more favorable than in adults. A multinational survey of 135 children with juvenile systemic sclerosis found a significantly better survival rate than in adult-onset patients at five years of follow-up, with a favorable outcome in most.¹⁹ That said, a more recent comparison that matched juvenile and adult patients by autoantibody type found that cumulative survival did not differ significantly between the two groups once antibody profiles were accounted for.²⁰ The favorable impression of juvenile SSc may partly reflect differences in the distribution of antibody subtypes between children and adults, rather than something inherently protective about being young.

The Digestive Tract and Quality of Life

One aspect of scleroderma that often gets overshadowed by discussions of skin, lungs, and kidneys is the gastrointestinal system. Gut involvement is actually one of the most common manifestations, ranging from mild acid reflux to severe dysmotility that can cause malabsorption, weight loss, and serious nutritional problems. These symptoms tend to wax and wane rather than follow a clear trajectory toward remission. Managing them involves a combination of medications to improve motility and reduce reflux, dietary adjustments, and sometimes nutritional support.

Across all organ systems, a large study tracking quality of life over time in SSc patients found that hand function, walking ability, mouth opening, and grip strength were all independently associated with worsening quality of life as the disease progressed.²¹ This is why rehabilitation and physical therapy play a role that often surprises patients. Even when the underlying disease cannot be cured, maintaining hand mobility, exercise capacity, and daily function is critical to how patients actually experience their disease. Early research found that even a single course of physical therapy could produce measurable improvement in hand function in scleroderma patients.²² Physical function is, in many ways, the patient’s personal definition of remission: can I use my hands, walk comfortably, eat without trouble, and breathe without strain?

When Scleroderma Overlaps With Other Autoimmune Diseases

Scleroderma does not always appear in isolation. Overlap syndromes, where features of SSc coexist with those of lupus, polymyositis, or rheumatoid arthritis, affect a meaningful subset of patients. These overlap patients may carry antibodies like anti-U1-RNP that are more typical of mixed connective tissue disease, or anti-PM-Scl antibodies that signal myositis overlap.¹⁷ Overlap syndromes can complicate the remission question because the non-scleroderma components of the disease may respond well to immunosuppression (lupus flares, inflammatory myositis) while the fibrotic scleroderma component does not. You can end up in a situation where some parts of the disease are in remission and others are not, which makes the patient’s experience quite different from someone with pure SSc.

For the same reason, patients with scleroderma overlap syndromes sometimes receive treatments borrowed from the other disease, such as rituximab for lupus-like features or intravenous immunoglobulin for myositis features. The response can be encouraging for the inflammatory components while the fibrotic aspects remain stubbornly stable. Managing expectations around this mixed picture is one of the trickier parts of caring for overlap patients.